Mid-treatment response to 177Lu-DOTATATE – A possible estimate for final outcome in patients with neuroendocrine neoplasms

#3817

Introduction: Patients with advanced or unresectable neuroendocrine neoplasm (NENs) have limited systemic treatment modalities. Among the patients receiving peptide receptor radionuclide therapy (PRRT) treatment with 177Lu-DOTATATE, a subset will require further chemotherapy in later stages. Hence, limiting radiation exposure is of paramount importance. However, there are no mid-term predictive factors for response to PRRT.

Aim(s): Assess the utility of mid-treatment (post 2nd cycle) response to PRRT as a potential predictor for final outcome in patients with well-differentiated NENs.

Materials and methods: A retrospective study, including patients that underwent at least 4 cycles of PRRT. Data gathered included demographics, tumor grade and stage, treatment response (stable disease [SD], partial response [PR] and progressive disease [PD]) evaluated by 68Ga-DOTATATE PET CT after 2nd and 4th treatment cycle, compared to pre-treatment scan.

Conference:

Presenting Author:

Authors: Halperin R, Tirosh A,

Keywords: PRRT, predictive factor, response, peptide receptor radionuclide therapy, efficacy, well-differentiated,